Phone Number: +16*********
Who is INSPIRNA
Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unm...
Read More
- Headquarters: 310 E 67th St, New York, New York, 10065, United States
- Date Founded: 2010
- Employees: 11-50
- Revenue: $10 Million to $25 Million
- Active Tech Stack: See technologies
- CEO: Usman Azam
Industry: Biotechnology
SIC Code: 2834 | NAICS Code: 561110 | Show More
Inspirna Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Inspirna
Answer: Inspirna's headquarters are located at 310 E 67th St, New York, 10065, United States
Answer: Inspirna's phone number is +16*********
Answer: Inspirna's official website is https://rgenix.com
Answer: Inspirna's revenue is $10 Million to $25 Million
Answer: Inspirna's SIC: 2834
Answer: Inspirna's NAICS: 561110
Answer: Inspirna has 11-50 employees
Answer: Inspirna is in Biotechnology
Answer: Inspirna contact info: Phone number: +16********* Website: https://rgenix.com
Answer: Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. Inspirnas lead drug candidate, ompenaclid (RGX-202), is an orally-administered small molecule that targets the CKB/SLC6A8 pathway, which when activated enables the generation of ATP in response to tumor hypoxia. Ompenaclid is currently being tested in multiple mid-stage clinical trials in patients with advanced or metastatic RAS mutant colorectal cancer. Inspirnas second clinical stage drug candidate, abequolixron (RGX-104), is an oral small molecule activator of LXR/APOE that inhibits angiogenesis and tumor myeloid derived suppressor cells to enhance the immune response against tumors. Abequolixron is currently being tested in a Phase 1b/2 clinical trial in patients with advanced or metastatic lung cancer in combination with docetaxel and endometrial cancer in combination with ipilimumab through a clinical collaboration with Bristol Myers Squibb. Inspirna identifies novel cancer targets using its microRNA-based target discovery platform, RNA-DRIVEr, which was originally developed by Inspirnas scientific co-founders at The Rockefeller University and exclusively licensed to Inspirna. The Company brings together distinguished scientific founders, a seasoned board of directors, and a leadership team comprised of experienced drug developers.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month